Arc 11The Gene Patent War
Wei Kang and Sanqing faced patent lawsuits and a blocked Eagle Country market while developing a new gene-editing technology. The conflict eased as the Broad Institute withdrew its suit, and Syngenta expanded Super Soybean sales abroad while Sanqing shifted its Feizhou drug strategy toward local partnerships and aid.
- Consumers rushed to buy domestic cooking oil after Super Soybean’s record yield drew attention, and Wei Kang praised General Manager Wang’s publicity campaign.
- Wei Kang tasked Tang Que with finding an independent gene-editing tool, and Three Purities’ Gene Laboratory began working with the China Academy of Sciences.
- Zheng Feng and Wei Kang settled the Broad Institute’s first patent dispute by agreeing that Sanqing would pay 25% of profits on each Thalassemia Gene Drug sold.
- After the Broad Institute filed suit and the FDA halted Sanqing’s Eagle Country sales, Tang Que revealed a new protease from an ancient Antarctic bacterium and a promising upgraded gene drug.
- Zheng Feng joined forces with Dr. Dudna to revoke Sanqing’s CRISPR licenses, but Three Purities won the Chinese jurisdiction dispute and the Broad Institute later withdrew its lawsuit.
- Wang De secured a Tanzanian agreement for farmers to grow Super Soybeans for guaranteed purchase, then negotiated seed and fertilizer sales with other foreign delegations.
- After the WHO removed Three Purities from its prequalified medicines list, Wei Kang withdrew its application and directed Zhang Chunming to pursue government cooperation, pharmacies, and aid organizations.
- Zhang Chunming arranged for Sanqing medicines to be donated or sold at cost to secure the release of Zhu Shan and two other Chinese men held in Zhongfei Country.